Neoadjuvant treatment of high-risk, clinically localized prostate cancer prior to radical prostatectomy Journal Article


Authors: Pietzak, E. J.; Eastham, J. A.
Article Title: Neoadjuvant treatment of high-risk, clinically localized prostate cancer prior to radical prostatectomy
Abstract: Multimodal strategies combining local and systemic therapy offer the greatest chance of cure for many with men with high-risk prostate cancer who may harbor occult metastatic disease. However, no systemic therapy combined with radical prostatectomy has proven beneficial. This was in part due to a lack of effective systemic agents; however, there have been several advancements in the metastatic and castrate-resistant prostate cancer that might prove beneficial if given earlier in the natural history of the disease. For example, novel hormonal agents have recently been approved for castration-resistant prostate cancer with some early phase II neoadjuvant showing promise. Additionally, combination therapy with docetaxel-based chemohormonal has demonstrated a profound survival benefit in metastatic hormone-naïve patients and might have a role in eliminating pre-existing ADT-resistant tumor cells in the neoadjuvant setting. The Cancer and Leukemia Group B (CALGB)/Alliance 90203 trial has finished accrual and should answer the question as to whether neoadjuvant docetaxel-based chemohormonal therapy provides an advantage over prostatectomy alone. There are also several promising targeted agents and immunotherapies under investigation in phase I/II trials with the potential to provide benefit in the neoadjuvant setting. © 2016, Springer Science+Business Media New York.
Keywords: neoadjuvant therapy; prostate cancer; radical prostatectomy; chemohormonal therapy
Journal Title: Current Urology Reports
Volume: 17
Issue: 5
ISSN: 1527-2737
Publisher: Springer  
Date Published: 2016-05-01
Start Page: 37
Language: English
DOI: 10.1007/s11934-016-0592-4
PROVIDER: scopus
PUBMED: 26968417
DOI/URL:
Notes: Review -- Export Date: 4 April 2016 -- Source: Scopus
Altmetric Score
MSK Authors
  1. James Eastham
    422 Eastham
  2. Eugene J Pietzak
    17 Pietzak